301 related articles for article (PubMed ID: 20082658)
1. Early defect of transforming growth factor β1 formation in Huntington's disease.
Battaglia G; Cannella M; Riozzi B; Orobello S; Maat-Schieman ML; Aronica E; Busceti CL; Ciarmiello A; Alberti S; Amico E; Sassone J; Sipione S; Bruno V; Frati L; Nicoletti F; Squitieri F
J Cell Mol Med; 2011 Mar; 15(3):555-71. PubMed ID: 20082658
[TBL] [Abstract][Full Text] [Related]
2. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
[TBL] [Abstract][Full Text] [Related]
3. Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice.
Wang H; Del Mar N; Deng Y; Reiner A
Neurosci Lett; 2021 Oct; 763():136180. PubMed ID: 34416343
[TBL] [Abstract][Full Text] [Related]
4. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
Hebb AL; Robertson HA; Denovan-Wright EM
Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
[TBL] [Abstract][Full Text] [Related]
5. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
Kuhn A; Goldstein DR; Hodges A; Strand AD; Sengstag T; Kooperberg C; Becanovic K; Pouladi MA; Sathasivam K; Cha JH; Hannan AJ; Hayden MR; Leavitt BR; Dunnett SB; Ferrante RJ; Albin R; Shelbourne P; Delorenzi M; Augood SJ; Faull RL; Olson JM; Bates GP; Jones L; Luthi-Carter R
Hum Mol Genet; 2007 Aug; 16(15):1845-61. PubMed ID: 17519223
[TBL] [Abstract][Full Text] [Related]
6. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
Seo H; Kim W; Isacson O
Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
[TBL] [Abstract][Full Text] [Related]
7. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways.
D'Onofrio M; Cuomo L; Battaglia G; Ngomba RT; Storto M; Kingston AE; Orzi F; De Blasi A; Di Iorio P; Nicoletti F; Bruno V
J Neurochem; 2001 Aug; 78(3):435-45. PubMed ID: 11483646
[TBL] [Abstract][Full Text] [Related]
9. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes.
Chou SY; Weng JY; Lai HL; Liao F; Sun SH; Tu PH; Dickson DW; Chern Y
J Neurosci; 2008 Mar; 28(13):3277-90. PubMed ID: 18367595
[TBL] [Abstract][Full Text] [Related]
10. The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.
Reiner A; Lafferty DC; Wang HB; Del Mar N; Deng YP
Neurobiol Dis; 2012 Jul; 47(1):75-91. PubMed ID: 22472187
[TBL] [Abstract][Full Text] [Related]
11. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
12. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
13. Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.
Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
J Pharmacol Exp Ther; 2021 Oct; 379(1):74-84. PubMed ID: 34330748
[TBL] [Abstract][Full Text] [Related]
14. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
[TBL] [Abstract][Full Text] [Related]
15. Astrocytes from cortex and striatum show differential responses to mitochondrial toxin and BDNF: implications for protection of striatal neurons expressing mutant huntingtin.
Saba J; López Couselo F; Turati J; Carniglia L; Durand D; de Laurentiis A; Lasaga M; Caruso C
J Neuroinflammation; 2020 Oct; 17(1):290. PubMed ID: 33023623
[TBL] [Abstract][Full Text] [Related]
16. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.
Schiefer J; Sprünken A; Puls C; Lüesse HG; Milkereit A; Milkereit E; Johann V; Kosinski CM
Brain Res; 2004 Sep; 1019(1-2):246-54. PubMed ID: 15306259
[TBL] [Abstract][Full Text] [Related]
17. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
Xie Y; Hayden MR; Xu B
J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
[TBL] [Abstract][Full Text] [Related]
18. R6/2 neurons with intranuclear inclusions survive for prolonged periods in the brains of chimeric mice.
Reiner A; Del Mar N; Deng YP; Meade CA; Sun Z; Goldowitz D
J Comp Neurol; 2007 Dec; 505(6):603-29. PubMed ID: 17948889
[TBL] [Abstract][Full Text] [Related]
19. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
[TBL] [Abstract][Full Text] [Related]
20. BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.
Reiner A; Wang HB; Del Mar N; Sakata K; Yoo W; Deng YP
Brain Res; 2012 Sep; 1473():161-72. PubMed ID: 22820300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
